Voranigo (Vorasidenib Citrate) Patent Expiration, LOE Window & CMS Spending

Voranigo (Vorasidenib Citrate) by Servier: FDA Orange Book core substance LOE 2039-01-16, 0 AB generics, $30.3M 2024 CMS Part D & Medicaid spend, and $39,881 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorServier
FDA Application & PathwayN218784 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-01-16
Last Listed Patent or Exclusivity Date2039-01-16
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$30.3M
2024 Medicare Part D Spend$19.2M
2024 Medicaid Spend$11.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($39,881 intro WAC)